The genome-wide association studies market size has grown rapidly in recent years. It will grow from $2.27 billion in 2025 to $2.58 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to expansion of genetic research initiatives, increasing availability of genomic datasets, growth in academic population studies, rising adoption of genotyping technologies, improvements in data analysis capabilities.
The genome-wide association studies market size is expected to see rapid growth in the next few years. It will grow to $4.26 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing demand for precision medicine insights, rising investments in genomic analytics platforms, expansion of ai-driven genetic research, growing pharmaceutical interest in target discovery, increasing focus on predictive healthcare models. Major trends in the forecast period include increasing adoption of large-scale population genomics studies, rising use of advanced bioinformatics platforms, growing integration of gwas in drug discovery, expansion of personalized medicine research programs, enhanced focus on disease risk prediction.
The increasing demand for personalized medicine is expected to drive the growth of the genome-wide association studies market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environment. Its growing adoption is largely driven by advancements in genomics that enable accurate identification of genetic variations and personalized treatment planning. Genome-wide association studies (GWAS) support personalized medicine by identifying genetic variants associated with diseases, allowing targeted therapeutic strategies. They enhance healthcare outcomes by improving risk assessment and enabling precision-based interventions. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Therefore, the increasing demand for personalized medicine is driving the expansion of the genome-wide association studies market.
Leading companies operating in the genome-wide association studies market are focusing on developing innovative solutions, such as advanced research platforms, to accelerate disease discovery and support personalized medicine applications. An advanced research platform is an integrated system of tools and technologies that enables large-scale genomic data generation, analysis, and interpretation for genome-wide association studies. For example, in January 2025, 23andMe Holding Co., a US-based biotechnology company, launched Discover23, a consumer-facing platform designed for genetic insights and ancestry exploration. The platform allows biopharmaceutical collaborators to access comprehensive genetic datasets within a secure environment powered by Lifebit. It delivers analysis-ready genome-wide association studies (GWAS) across more than 1,000 disease cohorts, derived from billions of phenotypic data points contributed by millions of consenting participants. This advanced research platform aims to accelerate drug discovery by enabling researchers to identify novel disease biology and potential therapeutic targets while improving clinical trial success and maintaining participant privacy.
In May 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired 23andMe Holding Co. for $256 million. Through this acquisition, Regeneron Pharmaceuticals plans to leverage one of the world’s largest consumer genetic databases to accelerate genomics-driven drug discovery, improve precision medicine, and advance health research while upholding strong data privacy and ethical standards. 23andMe Holding Co. is a US-based biotechnology company that provides genome-wide association studies.
Major companies operating in the genome-wide association studies market are F. Hoffmann-La Roche AG, AstraZeneca plc, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Eurofins Scientific SE, Laboratory Corporation of America Holdings, Daiichi Sankyo Company Limited, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Databricks Inc., Broad Institute of MIT and Harvard, BGI Genomics Co. Ltd., deCODE genetics Inc., Genomics England Ltd., CD Genomics Inc., Veritas Genetics Inc., Finngen, The Wellcome Sanger Institute.
North America was the largest region in the genome-wide association studies market in 2025. The regions covered in the genome-wide association studies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genome-wide association studies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the genome-wide association studies market by increasing costs of imported sequencing reagents, genotyping kits, laboratory consumables, and high-performance computing infrastructure. Pharmaceutical companies and research institutions in North America and Europe are most affected due to dependence on imported genomic tools, while Asia-Pacific faces cost pressures on reagent manufacturing and exports. These tariffs are raising study costs and extending research timelines. However, they are also encouraging local reagent production, regional bioinformatics development, and domestic investment in genomic research infrastructure.
The genome-wide association studies market research report is one of a series of new reports that provides genome-wide association studies market statistics, including genome-wide association studies industry global market size, regional shares, competitors with a genome-wide association studies market share, detailed genome-wide association studies market segments, market trends and opportunities, and any further data you may need to thrive in the genome-wide association studies industry. This genome-wide association studies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Genome-wide association studies (GWAS) are research investigations that examine the complete genomes of large populations to identify genetic variations linked to specific diseases or traits. These studies help identify genetic contributors to complex conditions or characteristics, supporting risk assessment, improving understanding of disease mechanisms, and guiding the development of targeted treatments.
The primary product types of genome-wide association studies are genotyping services, genotyping kits and reagents, software and data analysis tools, and others. Genotyping services are laboratory-based services that examine DNA to identify genetic variations for research, diagnostics, and personalized medicine. These services are applied in drug discovery, disease risk evaluation, personalized medicine, and other areas, serving end-users including pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinics, and others.
The genome-wide association studies market includes revenues earned by entities through sequencing, data analysis, bioinformatics support, biomarker discovery, and consulting for genetic association studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The genome-wide association studies market size is expected to see rapid growth in the next few years. It will grow to $4.26 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing demand for precision medicine insights, rising investments in genomic analytics platforms, expansion of ai-driven genetic research, growing pharmaceutical interest in target discovery, increasing focus on predictive healthcare models. Major trends in the forecast period include increasing adoption of large-scale population genomics studies, rising use of advanced bioinformatics platforms, growing integration of gwas in drug discovery, expansion of personalized medicine research programs, enhanced focus on disease risk prediction.
The increasing demand for personalized medicine is expected to drive the growth of the genome-wide association studies market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environment. Its growing adoption is largely driven by advancements in genomics that enable accurate identification of genetic variations and personalized treatment planning. Genome-wide association studies (GWAS) support personalized medicine by identifying genetic variants associated with diseases, allowing targeted therapeutic strategies. They enhance healthcare outcomes by improving risk assessment and enabling precision-based interventions. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Therefore, the increasing demand for personalized medicine is driving the expansion of the genome-wide association studies market.
Leading companies operating in the genome-wide association studies market are focusing on developing innovative solutions, such as advanced research platforms, to accelerate disease discovery and support personalized medicine applications. An advanced research platform is an integrated system of tools and technologies that enables large-scale genomic data generation, analysis, and interpretation for genome-wide association studies. For example, in January 2025, 23andMe Holding Co., a US-based biotechnology company, launched Discover23, a consumer-facing platform designed for genetic insights and ancestry exploration. The platform allows biopharmaceutical collaborators to access comprehensive genetic datasets within a secure environment powered by Lifebit. It delivers analysis-ready genome-wide association studies (GWAS) across more than 1,000 disease cohorts, derived from billions of phenotypic data points contributed by millions of consenting participants. This advanced research platform aims to accelerate drug discovery by enabling researchers to identify novel disease biology and potential therapeutic targets while improving clinical trial success and maintaining participant privacy.
In May 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired 23andMe Holding Co. for $256 million. Through this acquisition, Regeneron Pharmaceuticals plans to leverage one of the world’s largest consumer genetic databases to accelerate genomics-driven drug discovery, improve precision medicine, and advance health research while upholding strong data privacy and ethical standards. 23andMe Holding Co. is a US-based biotechnology company that provides genome-wide association studies.
Major companies operating in the genome-wide association studies market are F. Hoffmann-La Roche AG, AstraZeneca plc, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Eurofins Scientific SE, Laboratory Corporation of America Holdings, Daiichi Sankyo Company Limited, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Databricks Inc., Broad Institute of MIT and Harvard, BGI Genomics Co. Ltd., deCODE genetics Inc., Genomics England Ltd., CD Genomics Inc., Veritas Genetics Inc., Finngen, The Wellcome Sanger Institute.
North America was the largest region in the genome-wide association studies market in 2025. The regions covered in the genome-wide association studies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genome-wide association studies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the genome-wide association studies market by increasing costs of imported sequencing reagents, genotyping kits, laboratory consumables, and high-performance computing infrastructure. Pharmaceutical companies and research institutions in North America and Europe are most affected due to dependence on imported genomic tools, while Asia-Pacific faces cost pressures on reagent manufacturing and exports. These tariffs are raising study costs and extending research timelines. However, they are also encouraging local reagent production, regional bioinformatics development, and domestic investment in genomic research infrastructure.
The genome-wide association studies market research report is one of a series of new reports that provides genome-wide association studies market statistics, including genome-wide association studies industry global market size, regional shares, competitors with a genome-wide association studies market share, detailed genome-wide association studies market segments, market trends and opportunities, and any further data you may need to thrive in the genome-wide association studies industry. This genome-wide association studies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Genome-wide association studies (GWAS) are research investigations that examine the complete genomes of large populations to identify genetic variations linked to specific diseases or traits. These studies help identify genetic contributors to complex conditions or characteristics, supporting risk assessment, improving understanding of disease mechanisms, and guiding the development of targeted treatments.
The primary product types of genome-wide association studies are genotyping services, genotyping kits and reagents, software and data analysis tools, and others. Genotyping services are laboratory-based services that examine DNA to identify genetic variations for research, diagnostics, and personalized medicine. These services are applied in drug discovery, disease risk evaluation, personalized medicine, and other areas, serving end-users including pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinics, and others.
The genome-wide association studies market includes revenues earned by entities through sequencing, data analysis, bioinformatics support, biomarker discovery, and consulting for genetic association studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Genome-Wide Association Studies Market Characteristics
3. Genome-Wide Association Studies Market Supply Chain Analysis
4. Global Genome-Wide Association Studies Market Trends and Strategies
5. Genome-Wide Association Studies Market Analysis of End Use Industries
7. Global Genome-Wide Association Studies Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Genome-Wide Association Studies Total Addressable Market (TAM) Analysis for the Market
9. Genome-Wide Association Studies Market Segmentation
10. Genome-Wide Association Studies Market Regional and Country Analysis
11. Asia-Pacific Genome-Wide Association Studies Market
12. China Genome-Wide Association Studies Market
13. India Genome-Wide Association Studies Market
14. Japan Genome-Wide Association Studies Market
15. Australia Genome-Wide Association Studies Market
16. Indonesia Genome-Wide Association Studies Market
17. South Korea Genome-Wide Association Studies Market
18. Taiwan Genome-Wide Association Studies Market
19. South East Asia Genome-Wide Association Studies Market
20. Western Europe Genome-Wide Association Studies Market
21. UK Genome-Wide Association Studies Market
22. Germany Genome-Wide Association Studies Market
23. France Genome-Wide Association Studies Market
24. Italy Genome-Wide Association Studies Market
25. Spain Genome-Wide Association Studies Market
26. Eastern Europe Genome-Wide Association Studies Market
27. Russia Genome-Wide Association Studies Market
28. North America Genome-Wide Association Studies Market
29. USA Genome-Wide Association Studies Market
30. Canada Genome-Wide Association Studies Market
31. South America Genome-Wide Association Studies Market
32. Brazil Genome-Wide Association Studies Market
33. Middle East Genome-Wide Association Studies Market
34. Africa Genome-Wide Association Studies Market
36. Genome-Wide Association Studies Market Competitive Landscape and Company Profiles
37. Genome-Wide Association Studies Market Other Major and Innovative Companies
40. Genome-Wide Association Studies Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Genome-Wide Association Studies Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses genome-wide association studies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for genome-wide association studies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The genome-wide association studies market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Genotyping Services; Genotyping Kits And Reagents; Software And Data Analysis Tools; Other Product Types2) By Application: Drug Discovery; Disease Risk Assessment; Personalized Medicine; Other Applications
3) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Hospitals And Clinics; Other End-Users
Subsegments:
1) By Genotyping Services: Whole Genome Sequencing (Wgs); Exome Sequencing; Targeted Genotyping2) By Genotyping Kits And Reagents: Dna Extraction Kits; Sequencing Reagents; Library Preparation Kits
3) By Software And Data Analysis Tools: Bioinformatics Platforms; Data Visualization Tools; Statistical Analysis Software
4) By Other Product Types: Sample Collection Devices; Quality Control Tools; Laboratory Consumables
Companies Mentioned: F. Hoffmann-La Roche AG; AstraZeneca plc; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Regeneron Pharmaceuticals Inc.; Eurofins Scientific SE; Laboratory Corporation of America Holdings; Daiichi Sankyo Company Limited; Agilent Technologies Inc.; Illumina Inc.; Revvity Inc.; QIAGEN N.V.; Databricks Inc.; Broad Institute of MIT and Harvard; BGI Genomics Co. Ltd.; deCODE genetics Inc.; Genomics England Ltd.; CD Genomics Inc.; Veritas Genetics Inc.; Finngen; The Wellcome Sanger Institute
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Genome-Wide Association Studies market report include:- F. Hoffmann-La Roche AG
- AstraZeneca plc
- Thermo Fisher Scientific Inc.
- GlaxoSmithKline plc
- Regeneron Pharmaceuticals Inc.
- Eurofins Scientific SE
- Laboratory Corporation of America Holdings
- Daiichi Sankyo Company Limited
- Agilent Technologies Inc.
- Illumina Inc.
- Revvity Inc.
- QIAGEN N.V.
- Databricks Inc.
- Broad Institute of MIT and Harvard
- BGI Genomics Co. Ltd.
- deCODE genetics Inc.
- Genomics England Ltd.
- CD Genomics Inc.
- Veritas Genetics Inc.
- Finngen
- The Wellcome Sanger Institute
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.58 Billion |
| Forecasted Market Value ( USD | $ 4.26 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
